MSN Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • MSN Pharmaceuticals's estimated annual revenue is currently $45.2M per year.(i)
  • MSN Pharmaceuticals's estimated revenue per employee is $152,787

Employee Data

  • MSN Pharmaceuticals has 296 Employees.(i)
  • MSN Pharmaceuticals grew their employee count by 36% last year.

MSN Pharmaceuticals's People

NameTitleEmail/Phone
1
Associate Director Quality ControlReveal Email/Phone
2
Senior Human Resources ManagerReveal Email/Phone
3
Junior ManagerReveal Email/Phone
4
Assistant ManagerReveal Email/Phone
5
Senior Scientist, Formulations R&DReveal Email/Phone
6
Technical WriterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M2729%N/AN/A
#2
$35.8M1566%N/AN/A
#3
$5.4M2723%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M7250%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M4515%N/AN/A
#8
$10.3M6334%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is MSN Pharmaceuticals?

MSN Pharmaceuticals Inc. (MSNPI), a fully owned subsidiary of MSN Group of Companies, is one of the fast-emerging Finished Dosages manufacturers of USA. With its state-of-the-art manufacturing facility, located at Piscataway, New Jersey, MSNPI is endowed with the capability to deliver high-quality formulations in diverse dosage forms to the US and several other key regulatory markets. Backed by an expansive product portfolio, novel technological processes and the ability to handle large commercial volumes, MSNPI also caters to the custom manufacturing requirements of its clients. MSNPI led by a highly motivated team of employees is recognised for its proactive marketing, robust IP strategy, innovative R&D expertise and world-class production capabilities.

keywords:N/A

N/A

Total Funding

296

Number of Employees

$45.2M

Revenue (est)

36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$95.1M2986%N/A
#2
$55.5M30623%N/A
#3
$55.1M31524%N/A
#4
$87.9M34624%N/A
#5
$82.6M36727%N/A